Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-10-21
    E.g., 2018-10-21

Archive Search

259517 items
10:34 AM, Oct 19, 2018  |  BC Week In Review | Company News  |  Deals

GEn1E gains option to p38 MAPK inhibitor

GEn1E Lifesciences Inc. (Palo Alto, Calif.) gained an exclusive option to license a patent application from the University of Maryland Baltimore (Baltimore, Md.) covering methods and use of p38 mitogen-activated protein kinase (p38 MAPK; MAPK14)...
10:32 AM, Oct 19, 2018  |  BC Week In Review | Company News  |  Deals

Gurnet to acquire Corium as it heads for NDA

Healthcare investor Gurnet Point Capital will acquire drug delivery company Corium International Inc. (NASDAQ:CORI) for $12.50 per share in cash plus $0.50 per share in a contingent value right (CVR). The deal, including the CVR,...
10:25 AM, Oct 19, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Taris' TAR-302 reduces daily incontinence episodes by 75% in Phase Ib

Taris Biomedical LLC (Lexington, Mass.) reported Phase Ib data in August showing that TAR-302 reduced mean daily incontinence episodes by 75% at day 42 in idiopathic overactive bladder (OAB) patients who were experiencing an average...
10:21 AM, Oct 19, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Celgene's Otezla meets in Phase III for scalp psoriasis

Celgene Corp. (NASDAQ:CELG) said Otezla apremilast met the primary endpoint in the Phase III STYLE trial to treat moderate to severe plaque psoriasis of the scalp. A significantly greater proportion of patients who received twice-daily...
10:17 AM, Oct 19, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Novo's oral GLP-1 analog meets in Japanese Phase IIIa for Type II diabetes

Novo Nordisk A/S (CSE:NOVO B; NYSE:NVO) reported that oral semaglutide met the primary safety endpoint in the Japanese Phase IIIa PIONEER 10 trial to treat Type II diabetes. The open-label trial evaluated once-daily 3, 7...
10:16 AM, Oct 19, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Orphazyme seeking path forward for arimoclomol in NPC after Phase II/III miss

Orphazyme A/S (CSE:ORPHA) said arimoclomol missed the primary endpoints in a Phase II/III trial to treat Niemann-Pick disease type C (NPC). The company plans to meet with FDA and EMA to determine next steps for...
10:14 AM, Oct 19, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Viking's VK5211 meets primary in Phase II for acute hip fracture

Viking Therapeutics Inc. (NASDAQ:VKTX) said VK5211 met the primary endpoint of increasing lean body mass from baseline to week 12 vs. placebo in a Phase II trial in patients recovering from acute hip fracture surgery....
10:12 AM, Oct 19, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Genentech's Kadcyla meets in Phase III as breast cancer adjuvant

Genentech Inc. said adjuvant treatment with Kadcyla ado-trastuzumab emtansine met the primary endpoint of improving invasive disease-free survival (DFS) vs. Herceptin trastuzumab in the Phase III KATHERINE trial to treat breast cancer. The open-label, international...
10:11 AM, Oct 19, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Krystal's topical gene therapy meets endpoints in two patients with skin blistering disease

Krystal Biotech Inc. (NASDAQ:KRYS) reported interim data from the Phase I/II GEM trial showing that topical gene therapy KB103 met all primary efficacy and safety endpoints in two adults with recessive dystrophic epidermolysis bullosa. KB103 is...
10:09 AM, Oct 19, 2018  |  BC Week In Review | Clinical News  |  Clinical Results

Pharnext planning U.S, EU submissions for Charcot-Marie-Tooth therapy on Phase III data

Pharnext S.A. (Euronext:ALPHA) plans to submit regulatory applications to FDA and EMA in 2H19 for PXT3003 to treat mild to moderate Charcot-Marie-Tooth 1A (CMT1A) disease after a high dose of the compound met the primary...

Pages